Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 regimen-finding study in moderate to severe plaque psoriasis
2008-007525-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoint: PASI 75 response at week 13. Started Jun 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2008-007525-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007525-39.